Aster DM Healthcare Q1 FY25 Results:
Key Financial Highlights
Revenue grew 20% YoY to INR 1,002 Crs. in Q1 FY25 Vs. INR 838 Crs. in Q1 FY24.
Operating EBITDA grew 39% YoY to INR 177 Crs. in Q1 FY25 Vs. INR 128 Crs. in Q1 FY24.
Operating EBITDA Margins stood at 17.7% in Q1 FY25 Vs. 15.3% in Q1 FY24
PBT grew by 125% YoY to INR 123 Crs. in Q1 FY25 Vs. INR 54 Crs. in Q1 FY24.
Net Profit (post NCI) grew by 80% to INR 74 Crs. in Q1 FY25 Vs. INR 41 Crs. in Q1 FY24.
Commenting on the performance for Q1 FY25, Dr. Azad Moopen, Founder and Chairman, Aster DM Healthcare, said: “I am pleased to announce that this quarter represents a pivotal moment for Aster DM Healthcare. With the successful segregation of our GCC business, we are now a pure-play India entity, as we embark on a new journey FY25 onwards. In Q1 FY25, our India business achieved 20% YoY growth delivering the highest ever revenue performance of INR 1,002 crores, aided by an increase in bed capacity and growth in ARPOB. The Operating EBITDA grew by 39% YoY to INR 177 crores and net profits (post NCI) grew by 80% YoY to INR 74 crores in Q1 FY25”
Dr. Moopen further added, “Aster DM Healthcare continues to get prestigious recognitions at the national level. Recently, The Economic Times awarded us as the “Best Healthcare Brand of the Year-2024”. Also, Aster CMI Hospital became the first hospital in South India to receive NABH Digital Platinum Accreditation. As we progress, we are on track to reach 6,500+ beds by FY27, further strengthening our position as a leader in the healthcare sector.”
India Performance Highlights
Core Hospital & Clinics business delivered Operating EBITDA margin of ~21% in Q1 FY25.
Matured Hospital’s (>6 years since commencement) Operating EBITDA margins at 23.2% in Q1 FY25
Whitefield hospital (Bangalore) achieved 65% occupancy levels and ARPOB is above INR 70k+ in Q1 FY25
Payor mix improved with Insurance business at 30% (i.e. +200 bps), offset by lower scheme business.
Karnataka & Maharashtra cluster revenue grew by 38% YoY and operating EBITDA grew by 55% YoY
Aster Labs revenue grew by 15% YoY in Q1 FY25, continuing to deliver positive operating EBITDA margin. (Pressnote)
.jfif)
